Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a ...

DISP-10 is a novel tumor-specific virus and CAR T combination designed to overcome key challenges of applying CAR T therapy to solid tumors DISP-10 has broad potential to target all solid tumors of ...

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the ...

RIDE-001 was developed using Trained Therapeutix’s proprietary ApoA1-based nanomedicines platform to target the bone marrow where it activates the intracellular pattern recognition receptor NOD2. This ...

Tech firms are floating the idea of building data centers in space and tapping into the sun's energy to meet ...

Vera Therapeutics (VERA) announced data from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy were presented as a featured late-breaking ...

Australia announces the "Solar Sharer" program for free daily power. All households will benefit, driving major changes in ...

Surya Ganguli, Surbhi Goel and Krishna Pillutla among scholars to receive $18 million in AI2050 fellowships for AI research ...

The latest research adds a dimension of clarity to sea otter health. So do new discoveries about the ways to treat ...

The sports data and betting technology landscape has undergone a seismic transformation over the past two decades, and at the ...

In Texas, which has the second-largest population of immigrants living illegally in the country — with more than 1.6 million ...

Could a 322-foot-tall rocket really change how we reach Mars? Blue Origin is betting on it. On Nov. 9, the company will try ...